Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

148.41 -1.43 (-0.95%)
Streaming Delayed Price Updated: 11:21 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
51 52 Next >
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Stocks Stall On November 21, 2023, As Systematic Flows Abate ↗
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied 
Via Talk Markets
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today ↗
 
Via Benzinga
News headline image
Is NASDAQ:GILD suited for dividend investing? ↗
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
News headline image
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
News headline image
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals. ↗
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying. 
Via Chartmill
News headline image
Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
A Closer Look at Gilead Sciences's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Where Gilead Sciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
Gilead Sciences Tops Q3 Earnings And Revenue Estimates ↗
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
News headline image
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript ↗
GILD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Gilead Sciences ↗
 
Via Benzinga
News headline image
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why ↗
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's  
Via Benzinga
News headline image
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs ↗
The biotech company makes three notable treatments for cancer. 
Via Investor's Business Daily
News headline image
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity ↗
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
News headline image
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto ↗
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
News headline image
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets ↗
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
News headline image
Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook ↗
Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.  
Via Benzinga
News headline image
3 Pharma Stocks That Are Screaming Buys in October ↗
Each company delivers an above-average dividend and revenue growth. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
7 Healthcare Stocks to invest in for a Healthy Future ↗
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
News headline image
Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase ↗
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.  
Via Benzinga
News headline image
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock ↗
The companies are hoping to use antibody drug conjugates in lung cancer patients. 
Via Investor's Business Daily
News headline image
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? ↗
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! 
Via InvestorPlace
News headline image
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why ↗
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.